![]() |
||||
|
|
||||
|
|
||||
|
|
Re: BextraFrom: anonymous@obgyn.netSat Apr 19 10:26:55 2003
Posted to the ERC Listserve in November 2002 -- According to Medwatch, the FDA and Pharmacia/Pfizer have strengthened the CONTRAINDICATIONS, WARNINGS, and ADVERSE REACTIONS sections of the prescribing information for Bextra (valdecoxib). In postmarketing experience, rare reports of hypersensitivity reactions (i.e, anaphylatic reactions and angioedema) and skin reactions, including cases of Stevens-Johnson syndrome, toxic epidermal necrolysis, exfoliative dermatitis, and erythema multiforme, have been received. These cases, some of which were serious/life threatening, have occured in patients with and without a history of allergic type reations to sulfonamides. To read the MedWatch 2002 Bextra safety alert, including links to the "Dear Healthcare Professional" letter and an FDA Talk Paper, go to: http://www.fda.gov/medwatch/SAFETY/2002/safety02.htm#bextra
|
|
Return to ![]()
Technical Problems: webmaster@obgyn.net
Last Updated: Wed Dec 2 03:43:25 2009
Women's Insurance Checklist from Auto Insurance Quote
home | medical professionals | women | industry | forums | international